ArticleFrontiers in microbiology2025
Clinical features and gut microbiota alterations in hypertensive individuals with left ventricular hypertrophy.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify potential diagnostic biomarkers for individuals with hypertension and left ventricular hypertrophy (LVH) by characterizing associated clinical features and gut microbiota profiles. Methods: Participants were classified into three groups: a hypertrophy group (hypertension with LVH, Results: Patients in the hypertrophy group exhibited elevated body mass index (BMI), uric acid, triglycerides, and homocysteine levels, as well as reduced estimated glomerular filtration rate and high-density lipoprotein cholesterol. Structural cardiac changes were more pronounced in this group. Increased BMI and γ-glutamyl transferase levels emerged as independent risk factors for LVH. A significant reduction in Actinobacteria abundance was observed in the hypertrophy group compared to healthy controls. At the genus level, microbial compositions in the non-hypertrophy and control groups were more similar. Conclusion: Patients with hypertension and LVH demonstrated distinct metabolic abnormalities and alterations in gut microbiota composition. These findings reported potential microbial biomarkers and pathways for the prevention and management of hypertension-related target organ damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.